{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B-cell+Non-Hodgkin+Lymphoma&page=45",
    "query": {
      "condition": "Refractory B-cell Non-Hodgkin Lymphoma",
      "page": 45
    },
    "page_size": 10
  },
  "pagination": {
    "page": 45,
    "page_size": 10,
    "total_count": 1227,
    "total_pages": 123,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B-cell+Non-Hodgkin+Lymphoma&page=46&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B-cell+Non-Hodgkin+Lymphoma&page=44&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T17:46:11.944Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02384954",
      "title": "QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "N-803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Altor BioScience",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2015-04-17",
      "completion_date": "2020-12-13",
      "has_results": true,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-10-19T17:46:11.944Z",
      "location_count": 4,
      "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02384954"
    },
    {
      "nct_id": "NCT02109224",
      "title": "Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult B Acute Lymphoblastic Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Cutaneous B-Cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "HIV Infection",
        "Intraocular Lymphoma",
        "Multicentric Angiofollicular Lymphoid Hyperplasia",
        "Nodal Marginal Zone Lymphoma",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Immunoblastic Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hairy Cell Leukemia",
        "Refractory Plasma Cell Myeloma",
        "Small Intestinal Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Testicular Lymphoma",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2014-09",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-08-20",
      "last_synced_at": "2026-10-19T17:46:11.944Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02109224"
    },
    {
      "nct_id": "NCT00006473",
      "title": "Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Angioimmunoblastic T-cell Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2000-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-23",
      "last_synced_at": "2026-10-19T17:46:11.944Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006473"
    },
    {
      "nct_id": "NCT04404283",
      "title": "Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Brentuximab vedotin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 239,
      "start_date": "2020-08-20",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-19T17:46:11.944Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Bonita Springs, Florida + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Bonita Springs",
          "state": "Florida"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04404283"
    },
    {
      "nct_id": "NCT03682796",
      "title": "Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Lymphoma, B-Cell",
        "Lymphoma, Non-Hodgkin",
        "Lymphoma, Mantle-Cell",
        "Lymphoma, Marginal Zone",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma, Follicular"
      ],
      "interventions": [
        {
          "name": "TRPH-222",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Triphase Research and Development III Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2018-10-15",
      "completion_date": "2021-11-17",
      "has_results": false,
      "last_update_posted_date": "2022-05-19",
      "last_synced_at": "2026-10-19T17:46:11.944Z",
      "location_count": 5,
      "location_summary": "Gilbert, Arizona • Buffalo, New York • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03682796"
    },
    {
      "nct_id": "NCT00002461",
      "title": "Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "autologous bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "in vitro-treated bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "15 Years to 65 Years"
      },
      "enrollment_count": 35,
      "start_date": "1988-04",
      "completion_date": "1991-07",
      "has_results": false,
      "last_update_posted_date": "2018-08-17",
      "last_synced_at": "2026-10-19T17:46:11.944Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002461"
    },
    {
      "nct_id": "NCT00081861",
      "title": "Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Avastin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2004-03",
      "completion_date": "2007-09",
      "has_results": true,
      "last_update_posted_date": "2012-04-05",
      "last_synced_at": "2026-10-19T17:46:11.944Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00081861"
    },
    {
      "nct_id": "NCT03320642",
      "title": "GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "Itacitinib",
          "type": "DRUG"
        },
        {
          "name": "Calcineurin inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2018-02-27",
      "completion_date": "2022-02-17",
      "has_results": false,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-10-19T17:46:11.944Z",
      "location_count": 9,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Maywood, Illinois + 6 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03320642"
    },
    {
      "nct_id": "NCT01053494",
      "title": "Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia",
        "Acute Undifferentiated Leukemia",
        "Angioimmunoblastic T-cell Lymphoma",
        "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative",
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Burkitt Lymphoma",
        "Childhood Acute Lymphoblastic Leukemia in Remission",
        "Childhood Acute Myeloid Leukemia in Remission",
        "Childhood Chronic Myelogenous Leukemia",
        "Childhood Diffuse Large Cell Lymphoma",
        "Childhood Grade III Lymphomatoid Granulomatosis",
        "Childhood Immunoblastic Large Cell Lymphoma",
        "Childhood Myelodysplastic Syndromes",
        "Childhood Nasal Type Extranodal NK/T-cell Lymphoma",
        "Chronic Eosinophilic Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Chronic Neutrophilic Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "Contiguous Stage II Mantle Cell Lymphoma",
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "Essential Thrombocythemia",
        "Extramedullary Plasmacytoma",
        "Intraocular Lymphoma",
        "Isolated Plasmacytoma of Bone",
        "Juvenile Myelomonocytic Leukemia",
        "Mast Cell Leukemia",
        "Meningeal Chronic Myelogenous Leukemia",
        "Noncontiguous Stage II Mantle Cell Lymphoma",
        "Polycythemia Vera",
        "Post-transplant Lymphoproliferative Disorder",
        "Primary Myelofibrosis",
        "Primary Systemic Amyloidosis",
        "Progressive Hairy Cell Leukemia, Initial Treatment",
        "Prolymphocytic Leukemia",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Childhood Anaplastic Large Cell Lymphoma",
        "Recurrent Childhood Grade III Lymphomatoid Granulomatosis",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Small Noncleaved Cell Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent/Refractory Childhood Hodgkin Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hairy Cell Leukemia",
        "Refractory Multiple Myeloma",
        "Relapsing Chronic Myelogenous Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Stage 0 Chronic Lymphocytic Leukemia",
        "Stage I Childhood Anaplastic Large Cell Lymphoma",
        "Stage I Childhood Hodgkin Lymphoma",
        "Stage I Childhood Large Cell Lymphoma",
        "Stage I Childhood Lymphoblastic Lymphoma",
        "Stage I Childhood Small Noncleaved Cell Lymphoma",
        "Stage I Chronic Lymphocytic Leukemia",
        "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage I Multiple Myeloma",
        "Stage I Mycosis Fungoides/Sezary Syndrome",
        "Stage II Childhood Anaplastic Large Cell Lymphoma",
        "Stage II Childhood Hodgkin Lymphoma",
        "Stage II Childhood Large Cell Lymphoma",
        "Stage II Childhood Lymphoblastic Lymphoma",
        "Stage II Childhood Small Noncleaved Cell Lymphoma",
        "Stage II Chronic Lymphocytic Leukemia",
        "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage II Multiple Myeloma",
        "Stage II Mycosis Fungoides/Sezary Syndrome",
        "Stage III Childhood Anaplastic Large Cell Lymphoma",
        "Stage III Childhood Hodgkin Lymphoma",
        "Stage III Childhood Large Cell Lymphoma",
        "Stage III Childhood Lymphoblastic Lymphoma",
        "Stage III Childhood Small Noncleaved Cell Lymphoma",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage III Multiple Myeloma",
        "Stage III Mycosis Fungoides/Sezary Syndrome",
        "Stage IV Childhood Anaplastic Large Cell Lymphoma",
        "Stage IV Childhood Hodgkin Lymphoma",
        "Stage IV Childhood Large Cell Lymphoma",
        "Stage IV Childhood Lymphoblastic Lymphoma",
        "Stage IV Childhood Small Noncleaved Cell Lymphoma",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage IV Mycosis Fungoides/Sezary Syndrome",
        "T-cell Large Granular Lymphocyte Leukemia",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "massage therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "intervention by caregiver",
          "type": "OTHER"
        },
        {
          "name": "standard follow-up care",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 80,
      "start_date": "2010-04",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2018-07-02",
      "last_synced_at": "2026-10-19T17:46:11.944Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01053494"
    },
    {
      "nct_id": "NCT06176690",
      "title": "Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "CD30-Positive Diffuse Large B-Cell Lymphoma",
        "Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type",
        "Anaplastic Large Cell Lymphoma, ALK-Positive",
        "Peripheral T-cell Lymphoma",
        "Anaplastic Large Cell Lymphoma, ALK-negative",
        "Non-Hodgkin Lymphoma",
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "C7R.CD30.CAR-EBVST cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 90,
      "start_date": "2025-10-27",
      "completion_date": "2043-06-27",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-19T17:46:11.944Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06176690"
    }
  ]
}